Can Peripheral Restriction Give CB1 a Second Chance in Obesity?
What CRB-913 may tell us about revisiting an old obesity target through tissue-selective pharmacology
Cannabinoid receptor 1 (CB1) is not a new target in obesity. In fact, it provides an interesting example of a target that showed clinical efficacy but was ultimately limited by the pharmacological properties of the drugs developed against it.
One of the best-known examples is rimonabant (SR141716), a CB1 receptor antagonist/inverse agonist developed for the treatment of obesity. Clinical studies showed that blocking CB1 could reduce body weight and improve several metabolic parameters. However, rimonabant readily entered the brain and blocked central CB1 signaling, which was associated with psychiatric adverse effects, including anxiety and depression. These safety concerns ultimately led to its withdrawal from the market.
But this raises an interesting question: Was CB1 itself the wrong target, or was blocking CB1 in the brain the problem?
Why peripheral CB1 may still matter
CB1 receptors are widely expressed in metabolically relevant peripheral tissues, including the liver, adipose tissue, skeletal muscle, and pancreas. CB1 signaling is therefore not limited to the central nervous system.
Several preclinical studies have suggested that excessive peripheral CB1 signaling in obesity may contribute to hepatic steatosis, insulin resistance, and disrupted lipid and energy metabolism. In contrast, blocking peripheral CB1 signaling may improve these metabolic abnormalities without requiring substantial CB1 receptor occupancy in the brain.
This leads to a relatively simple therapeutic hypothesis: Can we preserve the metabolic benefits of CB1 inhibition while keeping the drug largely out of the brain?
CRB-913 provides an early human test of this idea
Corbus Pharmaceuticals recently reported topline results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist.
The study included 254 adults with obesity but without diabetes. After 12 weeks of treatment, the 60 mg group achieved a placebo-adjusted mean body-weight reduction of approximately 5.0%, compared with 3.3% in the 40 mg group and 2.8% in the 20 mg group. Notably, weight loss did not appear to have plateaued by Week 12.
Corbus has also reported substantially lower brain exposure with CRB-913 compared with earlier CB1-targeting compounds. In CANYON-1, the company reported that psychiatric adverse events were broadly consistent with published rates for GLP-1 therapies. However, given the relatively short duration and early stage of the trial, larger and longer studies will be needed to better assess its CNS safety profile.
What I find interesting
To me, the most interesting part of these results is not the 5% weight-loss number itself.
What makes CRB-913 particularly interesting is the broader drug-development concept it is testing: a target previously limited by safety concerns may become therapeutically useful again if we can change where the drug acts.
There is also an important metabolic question.
If peripheral CB1 blockade directly affects adipose and hepatic metabolism, its potential benefits may extend beyond appetite suppression and weight loss. I would be particularly interested in seeing future data on:
Get Gavin Shou’s stories in your inbox
Join Medium for free to get updates from this writer.
biomarkers of peripheral CB1 target engagement
liver fat
insulin sensitivity
circulating lipids
fat versus lean mass loss
energy expenditure
These measurements could help determine whether peripheral CB1 inhibition produces a metabolic phenotype that is meaningfully different from that of incretin-based therapies.
Where could this fit in the GLP-1 era?
I think it is still too early to frame CRB-913 as a competitor to GLP-1/GIP-based therapies. A more interesting question is whether peripheral CB1 inhibition can provide complementary metabolic effects.
Coming from a background in metabolic biology, particularly intestinal metabolism, ketogenesis, and bile acid signaling, I am especially interested in how metabolic pathways across different tissues contribute to whole-body energy homeostasis. From this perspective, the potential value of peripheral CB1 inhibition may not be limited to how much weight people lose, but also to how the underlying metabolic state changes.
If its metabolic effects are sufficiently distinct from incretin-mediated appetite suppression, peripheral CB1 blockade could potentially be explored as a standalone non-incretin approach or, eventually, as part of combination therapy.
For now, CANYON-1 provides an encouraging early Phase 1b signal, but it is far from proving that CB1 has been successfully “rescued.” Still, it makes the target worth watching again.
Sometimes, a failed drug does not necessarily mean a failed target. The problem may be where the drug acts.
References:
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397. PubMed
Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134.
Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012;16:167–179.
Cinar R, Godlewski G, Liu J, et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology. 2014;59:143–153.
Corbus Pharmaceuticals. Corbus Pharmaceuticals announces positive topline data from CANYON-1 study of daily oral CRB-913 for the treatment of obesity. September 14, 2026. Corbus Pharmaceuticals — CANYON-1 topline results
